HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory In Brief

This article was originally published in The Rose Sheet

Executive Summary

Wella buy gets green light: Federal Trade Commission grants regulatory approval to Procter & Gamble to proceed with its planned acquisition of German beauty firm Wella. P&G continues to pursue necessary regulatory and governmental approvals in other major markets including the EU, firm notes. P&G owns 79.17% of total registered share capital and about 84.9% of the value of outstanding shares of Wella following the close of the second and final tender period in June (1"The Rose Sheet" June 30, 2003, Finance In Brief)...

You may also be interested in...



Sunscreen ingredient

BASF seeks 90-day extension to respond to FDA request for data on octyl triazone sunscreen; previous deadline was Oct. 9. BASF maintains it needs more time to compile recent effectiveness data and that extension would allow for a " more comprehensive and complete docket" on the substance. Beiersdorf submits letter to FDA Oct. 7 in support of BASF's time and extent application for ingredient, noting German firm has used octyl triazone in its own sun care products outside the U.S. for more than five years without "unusual adverse event experience." FDA requested data on the ingredient in a July 11 Federal Register notice (1"The Rose Sheet" July 14, 2003, Regulatory In Brief)...

Sunscreen ingredient

BASF seeks 90-day extension to respond to FDA request for data on octyl triazone sunscreen; previous deadline was Oct. 9. BASF maintains it needs more time to compile recent effectiveness data and that extension would allow for a " more comprehensive and complete docket" on the substance. Beiersdorf submits letter to FDA Oct. 7 in support of BASF's time and extent application for ingredient, noting German firm has used octyl triazone in its own sun care products outside the U.S. for more than five years without "unusual adverse event experience." FDA requested data on the ingredient in a July 11 Federal Register notice (1"The Rose Sheet" July 14, 2003, Regulatory In Brief)...

Octyl Triazone Sales Of 400 Mil. Sunscreen Units Abroad Cited By FDA

Based on bulk material sales, nearly 400 mil. sunscreen dosage units containing octyl triazone have been sold in 35 countries, FDA notes in an evaluation of BASF's time and extent application for including the ingredient in the OTC sunscreen monograph

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011360

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel